INMED PHARMACEUTICALS INC. Proceeds from Issuance of Private Placement
INMED PHARMACEUTICALS INC. (INM) reported Proceeds from Issuance of Private Placement of $5.02 million for the 12-month period ending 2025-06-30, per its S-4 filed 2026-07-02.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2026-07-02
- INMED PHARMACEUTICALS INC. proceeds from issuance of private placement for the quarter ending 2025-06-30 was $663.67K.
- INMED PHARMACEUTICALS INC. proceeds from issuance of private placement for the quarter ending 2025-03-31 was $2.94M.
- INMED PHARMACEUTICALS INC. proceeds from issuance of private placement for the quarter ending 2024-12-31 was $396.15K.
- INMED PHARMACEUTICALS INC. proceeds from issuance of private placement for the quarter ending 2024-09-30 was $1.03M.
- INMED PHARMACEUTICALS INC. proceeds from issuance of private placement for fiscal 2023 was $10.68M, a 97.78% increase from fiscal 2022.
- INMED PHARMACEUTICALS INC. proceeds from issuance of private placement for fiscal 2022 was $5.40M, a 50.91% decline from fiscal 2021.
- INMED PHARMACEUTICALS INC. proceeds from issuance of private placement for fiscal 2021 was $11.00M.
| Period end | Proceeds from Issuance of Private Placement | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 6 month as first filed | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month | Proceeds from Issuance of Private Placement 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-06-30 | $663.67K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $3.60M derived: sum of 2 quarters · filed 2026-07-02 | $3.99M derived: sum of 3 quarters · filed 2026-07-02 | $5.02M S-4 · filed 2026-07-02 | $8.13M 10-K · filed 2025-09-23 | ||
| 2025-03-31 | $2.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $3.33M derived: sum of 2 quarters · filed 2025-05-12 | $4.36M 10-Q · filed 2025-05-12 | -$854.97K derived: sum of 4 quarters · filed 2026-07-02 | |||
| 2024-12-31 | $396.15K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | $1.43M 10-Q · filed 2025-02-12 | -$3.79M derived: sum of 3 quarters · filed 2026-07-02 | -$3.79M derived: sum of 4 quarters · filed 2026-07-02 | |||
| 2024-09-30 | $1.03M 10-Q · filed 2024-11-14 | -$4.19M derived: sum of 2 quarters · filed 2026-07-02 | -$4.19M derived: sum of 3 quarters · filed 2026-07-02 | ||||
| 2024-06-30 | -$5.22M derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | -$5.22M derived: sum of 2 quarters · filed 2026-07-02 | $0.00 S-4 · filed 2026-07-02 | $4.65M 10-K · filed 2024-09-30 | |||
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $5.22M 10-Q · filed 2025-05-12 | |||||
| 2023-12-31 | $5.22M 10-Q · filed 2025-02-12 | $4.65M 10-Q · filed 2024-02-13 | |||||
| 2023-06-30 | $10.68M 10-K · filed 2024-09-30 | ||||||
| 2022-12-31 | $10.74M 10-Q · filed 2024-02-13 | ||||||
| 2022-11-21 | $6.00M 10-K · filed 2024-09-30 | ||||||
| 2022-06-30 | $5.40M 10-K · filed 2022-09-23 | ||||||
| 2021-06-30 | $11.00M 10-K · filed 2021-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |